biospecimen banks

CPDR Patient Education Program

Industry-Sponsored Clinical Trials and Projects

The CRC maintains a comprehensive portfolio of both investigator-initiated and industrysponsored clinical trials that cover the entire patient's "life cycle." Some of the trials, though industry sponsored, were investigator-initiated trials for which a proposal was submitted by CPDR to obtain funding. There are two types of these studies:

  • One is when we approach the industry with a proposal and request funding under a collaborative type of agreement; the ownership and control remains with CPDR but costs are supported by the company. One example of this is the CPDR Prostate Cancer Quality of Life Study that has been ongoing since 2003 and has a current enrollment of more 1,600 men. This study is a unique asset to the program in that it looks at patient-reported outcomes; however, it is a very costly endeavor due to its labor intensiveness. The study includes administration of the EPIC questionnaire along with the SF-36v2® health questionnaire to men newly diagnosed with prostate cancer at baseline (before treatment), and at eight other time points subsequent to their treatment for three years. After submission of a proposal to GlaxoSmithKline, it was accepted by the company for funding on a year-to-year basis and has thus far received approval for three years of funding.

  • The other type of study is to take an idea to a company for another application or therapeutic target using that company's existing technology. This approach usually results in work being conducted under a traditional clinical trial agreement where CPDR conducts the study, is reimbursed for the time spent working on the trial, and the data are supplied to the company who uses their resources for analysis.

  • All trials and projects are carried out with full approval of the respective IRBs.

 

Current Clinical Trials

1. A Multicenter Clinical Study of the Sonablate®500 for the Treatment of Locally Recurrent Prostate Cancer With HIFU - Click Here for Information on the Trial

2. Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer
Click Here for Information on the Trial

3. - A Phase 3 Efficacy Study of a Recombinant Vaccinia Virus Vaccine to Treat Metastatic Prostate Cancer
Click Here for Information on the Trial

 

CURRENT EVENTS


WRNMMC UsToo!

Read the FEBRUARY 2014 Newsletter

 

CURRENT PUBLICATIONS



Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer

Thangapazham R, Saenz F, Katta S, Mohamed AA, Tan S-H, Petrovics G, Srivastava S and Dobi A.
BMC Cancer. 2014: Jan 13;14:16.
Abstract



ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer.

Gsponer JR, Braun M, Scheble VJ, Zellweger T, Rentsch CA, Bachmann A, Perner S, Sesterhenn IA, Srivastava S, Dobi A, Bubendorf L, Ruiz C.
Prostate Cancer Prostatic Dis. 2014 Jan 28. doi: 10.1038/pcan.2013.62. [Epub ahead of print]
Abstract